Evotec

Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Central Glass Germany develops and manufactures chemical base materials, cosmetic ingredients, and pharmaceutical intermediates.

RigeneranD is committed to develop biomedical devices supporting the culture of stem cells for pre-clinical and clinical applications.Founded in 2009 by Prof. Massimo Dominici and Prof. Pierfranco Conte, as a spin-off resulting from a joint venture between biomedical company RanD and researchers from the University of Modena and Reggio Emilia, Rigenerand owns proprietary technology to develop and produce biomedical tools to empower the ex-vivo phase of stem cells expansion combining the need of high cell yield with innovative biocompatible materials.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at treating life-threatening diseases. The company employs its proprietary Alphamer technology, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies towards specific pathogens, enhancing the body's immune response to fight infections. Centauri's approach features a dual mechanism of action: a moiety that directly targets cell surface antigens and a glycan effector domain that activates a robust pre-existing polyclonal immune response. This response facilitates cell death through mechanisms such as complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has produced promising pre-clinical data, showcasing significant enhancements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, along with in vivo proof of concept data across multiple infection models.

IMIDomics is a company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs) through innovative approaches in biomarker discovery and treatment monitoring. By leveraging the world's largest IMID biobank, along with extensive clinical expertise and advanced genomic analysis, IMIDomics aims to enhance patient care. The company has developed an analytical software platform that extracts valuable insights from vast amounts of molecular and clinical data, making it accessible for healthcare professionals without requiring specialized bioinformatics knowledge. This facilitates optimized treatment strategies for IMID patients. Headquartered at Vall d'Hebron Hospital in Barcelona, Spain, and with a presence at the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics is positioned at the forefront of research and application in the field of immune-mediated diseases.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

OxVax Ltd. is a spin-out company from the University of Oxford dedicated to developing an advanced dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's innovative technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a unique subset that presents promising properties for cancer immunotherapy. This approach seeks to provide effective treatment options for patients with intractable cancers, leveraging the potential of dendritic cells to enhance the immune response against tumors.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Argobio is a start-up studio focused on developing innovative therapeutic solutions and fostering the growth of biotech firms. It collaborates with leading European academic research institutes to identify and nurture early-stage projects, particularly in the areas of rare diseases, neurological disorders, oncology, and immunology. By providing financial support and operational expertise, Argobio aims to cultivate these projects before launching them as independent companies. The studio also seeks to create promising platform technologies that can lead to new therapeutic products, thereby enhancing the drug research and development process for startups in the biotechnology sector.

Autobahn Labs is a biotechnology company based in Palo Alto, California, focused on accelerating the development of novel therapeutics. Founded in 2018, it operates as a collaboration between an investor syndicate led by Samsara BioCapital and Evotec. The company identifies promising early-stage academic research projects and leverages Evotec's expertise in drug discovery and development, combined with Samsara's investment approach, to enhance patient health. Autobahn Labs provides acceleration services that include a dedicated team with deep scientific and operational knowledge, industrialized drug discovery capabilities, and funding to help research institutions advance their projects to preclinical drug candidates. Through these efforts, Autobahn Labs aims to transform innovative science into effective therapies for patients.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors. At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs. By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. Their mission is to develop drugs that succeed and complement PARP inhibitors and facilitate the cure of therapy resistant cancers.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Celmatix Inc. is a personalized medicine company focused on women's health, particularly in reproductive health and fertility. The company offers POLARIS, a web-based analytics platform designed to optimize a woman's fertility by assessing her likelihood of success with various treatment options based on individual clinical metrics. Additionally, Celmatix provides NOVA, a patient portal that enhances the clinic experience for patients. By leveraging predictive analytics and genomics, the company develops products that empower women to make informed decisions regarding their fertility while equipping healthcare providers with data-driven tools for improved patient care. Celmatix has established a strategic alliance with Evotec and is recognized for possessing the largest structured dataset on ovarian health and outcomes globally. Founded in 2009 and headquartered in New York, Celmatix is also involved in innovative research areas such as ovarian senescence and non-hormonal contraceptives.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from their facilities in the UK, Italy, and now Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world's leading private equity investors.

Forge Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapeutics, particularly novel antibiotics. The company employs a proprietary chemistry platform that targets metalloproteins, specifically metalloenzymes, to create selective inhibitors. By utilizing a combination of bioinorganic and medicinal chemistry, Forge aims to address the challenge of multi-drug resistant bacteria. Its approach allows for the development of small molecule inhibitors that can influence various biochemical processes, providing healthcare professionals with new tools to combat resistant infections effectively.

Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.

Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Sanofi is a global healthcare company based in Paris, France, dedicated to providing therapeutic solutions across various medical fields. The company specializes in areas including diabetes, oncology, immunology, cardiovascular diseases, and rare diseases. Sanofi offers a wide range of products, including treatments for Gaucher disease, Pompe disease, multiple sclerosis, and several types of cancer. Its portfolio features insulins, cholesterol-lowering medications, and anti-hypertensives, among others. Additionally, Sanofi produces vaccines and health solutions addressing allergies, infectious diseases, and chronic conditions. The company emphasizes research and development to create innovative treatments, leveraging its extensive expertise in oncology and other therapeutic areas. Sanofi is committed to improving patient outcomes through effective healthcare solutions while collaborating with various organizations to enhance its research capabilities. Incorporated in 1994, Sanofi continues to evolve its offerings to meet global health needs.

Euprotec is a preclinical contract research organization that specializes in providing research services to companies engaged in the discovery and development of new drugs. The organization focuses on therapeutic areas such as infections, respiratory diseases, and allergies, offering expertise to support the research and development processes of its clients. By collaborating with pharmaceutical and biotechnology firms, Euprotec plays a critical role in advancing the development of innovative treatments in these key medical fields.

Bionamics GmbH is an asset management company based in Hamburg, Germany, specializing in the management of life science assets. The firm focuses on bridging the gap between outstanding research projects and the pharmaceutical industry's requirements for pre-clinical and clinical development programs. Bionamics offers project management services to pharmaceutical companies, facilitating the acquisition and licensing of life science assets in their early stages. By connecting innovative research with industry needs, Bionamics plays a vital role in advancing drug development and enhancing therapeutic options.

Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.

Compound Focus, Inc. offers molecule compound management services for liquid and solid compounds.

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. They are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, they continuously expand and improve their technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Evotec (India) Private Limited provides drug discovery and development services for pharmaceutical, biotech, and fine chemical industries.

Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. Through its research initiatives, the company seeks to create innovative therapeutics that address significant unmet medical needs in the field of neuroscience.